Degrader

Integrating Degradation, Engagement, and Selectivity: CETSA® as a Framework for Degrader Validation

Validate your PROTAC from mechanism to selectivity – all in live cells.

Discover how CETSA® provides an integrated approach to degrader validation. This CDK9-targeted degrader case study demonstrates how CETSA delivers the complete picture, from confirming target loss to revealing off-target effects.

What you’ll learn:

Degrade first: Measure what matters

Quantify target degradation in live cells and primary human PBMCs with dose- and time-dependent readouts.

Confirm engagement inside live cells

Measure thermal stabilization to distinguish true target binding from non-productive interactions in intact cells.

Profile selectivity before it’s a problem

Reveal the full degrader impact: on-target degradation, neo-substrate effects, and downstream pathway modulation that conventional assays miss.

A workflow that scales from screening to clinic

The case study demonstrates how CETSA supports degrader development from early validation through translational studies in patient-derived cells.

Why CETSA for degrader research?

  • Physiologically relevant – intact, unmodified cells
  • Native proteins – no tagging required
  • Quantitative – kinetic readouts
  • Comprehensive – degradation, engagement, and selectivity in one workflow
  • Translational – applicable to patient PBMCs

Whether you’re validating a lead degrader or profiling selectivity for IND-enabling studies, this poster illustrates how CETSA provides the integrated data you need to move forward with confidence.

Download now to see the complete CDK9 degrader dataset and learn how CETSA can strengthen your PROTAC development program.